Algernon Announces Increase to Private Placement Financing to $750,000 and Close of Third Tranche

Executive Summary

• Algernon Health Inc. closed the third tranche of its non‑brokered private placement, raising CAD $352,500 (5,035,714 units at $0.07 per unit).
• The total financing to date now equals CAD $739,500 from 10,564,286 units across three tranches.
• Proceeds will be used to advance the company’s Alzheimer’s Disease program, open its first U.S. AD clinic, cover G&A expenses and provide working capital.

Key Details

• Financing Structure: Non‑brokered private placement consisting of three tranches (first & second closed Nov 14 & Nov 28 2025; third closed Dec 23 2025).
• Third Tranche Size: CAD $352,500 gross proceeds.
• Units Sold in Third Tranche: 5,035,714 units at CAD $0.07 per unit.
• Total Units Issued to Date: 10,564,286 units.
• Aggregate Proceeds to Date: CAD $739,500.
• Finder’s Fees: No cash finder’s fees were paid for the third tranche.
• Use of Proceeds:
• Advancement of Alzheimer’s Disease (“AD”) program, including opening the first U.S. AD clinic.
• General and administrative expenses.
• Working capital.
• Statutory Hold Period: Securities subject to a four‑month plus one day hold period under Canadian securities law.
• U.S. Offering Restrictions: Units not registered in the United States; cannot be offered or sold to U.S. persons absent an exemption.

Notable Quotes

(No direct quotes were included in the release.)